Tag: Mallinckrodt

March 20, 2017

Intellipharmaceutics Talks Abuse Deterrent Technologies

INN sat down with Intellipharmaceutics' CEO Dr. Isa Odidi, to talk about its abuse deterrent technologies and product pipeline.
February 10, 2017

Intellipharmaceutics Announces 2016 Year End Results

TORONTO, Feb. 10, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing...
October 14, 2016

Intellipharmaceutics Announces Third Quarter 2016 Results

Intellipharmaceutics International, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral...
October 12, 2016

Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Mallinckrodt

Intellipharmaceutics, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid...
February 29, 2016

Asterias Biotherapeutics Gets New President and CEO

Asterias Biotherapeutics Inc. (NYSEMKT:AST) announced that Stephen L. Cartt has been appointed president and CEO of the company, and has...
August 11, 2015

Therakos Bought by Mallinckrodt for $1.33 Billion

Mallinckrodt (NYSE:MNK) has announced that it will buy Therakos, a privately held immunotherapy company, for $1.33 billion.
June 30, 2014

Should You be Worried About Moly-99 Supply?

In short, yes. The supply situation for molybdenum-99 is precarious, and that could be a problem given that it's used...